- Home
- SKBL vs RCKT Comparison
SKBL vs RCKT Comparison
Compare SKBL & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKBL
- RCKT
- Stock Information
- Founded
- SKBL 2012
- RCKT 1999
- Country
- SKBL Hong Kong
- RCKT United States
- Employees
- SKBL N/A
- RCKT N/A
- Industry
- SKBL
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- SKBL
- RCKT Health Care
- Exchange
- SKBL NYSE
- RCKT Nasdaq
- Market Cap
- SKBL 302.6M
- RCKT 264.0M
- IPO Year
- SKBL 2025
- RCKT N/A
- Fundamental
- Price
- SKBL $1.49
- RCKT $3.00
- Analyst Decision
- SKBL
- RCKT Buy
- Analyst Count
- SKBL 0
- RCKT 13
- Target Price
- SKBL N/A
- RCKT $18.50
- AVG Volume (30 Days)
- SKBL 2.3M
- RCKT 3.7M
- Earning Date
- SKBL 01-01-0001
- RCKT 08-04-2025
- Dividend Yield
- SKBL N/A
- RCKT N/A
- EPS Growth
- SKBL N/A
- RCKT N/A
- EPS
- SKBL 0.03
- RCKT N/A
- Revenue
- SKBL $49,638,709.00
- RCKT N/A
- Revenue This Year
- SKBL N/A
- RCKT N/A
- Revenue Next Year
- SKBL N/A
- RCKT N/A
- P/E Ratio
- SKBL $45.44
- RCKT N/A
- Revenue Growth
- SKBL 9.58
- RCKT N/A
- 52 Week Low
- SKBL $0.99
- RCKT $2.19
- 52 Week High
- SKBL $14.25
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- SKBL N/A
- RCKT 45.55
- Support Level
- SKBL N/A
- RCKT $2.76
- Resistance Level
- SKBL N/A
- RCKT $3.24
- Average True Range (ATR)
- SKBL 0.00
- RCKT 0.19
- MACD
- SKBL 0.00
- RCKT 0.17
- Stochastic Oscillator
- SKBL 0.00
- RCKT 74.85
About SKBL SKYLINE BUILDERS GROUP HOLDING LIMI
Skyline Builders Group Holding Ltd is an holding company operates through its subsidiary. It is a Public Works Contractor company undertaking roads and drainage in Hong Kong. Its construction activities mainly include public civil engineering works, such as road and drainage works, in Hong Kong.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.